Aggressive Lymphomas
News
Bortezomib may overcome resistance in WM
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new...
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...
From the Journals
NHL patients report fear, isolation during chemo
The qualitative study found that patients reported feeling like they were on an “emotional roller coaster” during their treatment.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
News
FDA puts selinexor on fast track for DLBCL
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.
News
Selinexor on fast track for DLBCL
The U.S.
News
Combo appears safe, active in rel/ref NHL
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or...
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...
From the Journals
Novel risk factors for febrile neutropenia in NHL, solid tumors
Corticosteroid use was most strongly associated with chemotherapy-induced febrile neutropenia.
News
EC approves venetoclax in combo with rituximab
The European Commission (EC) has approved a new indication for venetoclax (Venclyxto®). The drug is now approved for use in combination with...